Antimicrobial drug-nutrition interactions: Consistency of information for generic drugs
Abstract
Background/Aim. Antimicrobial drug-nutrition interactions can compromise the efficacy and safety of therapeutic regimen, as well as the nutritional status of a patient. In order to prevent them, health professionals consult the reference information sources. Summary of Product Characteristics (SmPC) is the basis for reliable and objective informing, and in the case of generic products, the content of documents should be consistent. The aim of the study was to compare information on antimicrobial drug-nutrition interactions for generic products, and to consider the influence of relevant factors (the time of the first authorization and the number of generic products) on the outcome of evaluation. Methods. SmPCs for all generic antimicrobial products for systemic use were retrieved from the Medicines and Medical Devices Agency of Serbia website, and statements of interest were extracted from different sections and were compared. The comparison was based on classification of statements on interaction into one of five classes: “effect of nutrition status on drug action”, “effect of food in general on drug action”, “effect of specific nutrient on drug action”, “effect of drug on nutrient and metabolic status”, or “effect of drug on nutrition status”. Results. A total of 160 SmPCs were evaluated for 30 antimicrobial drugs corresponding to 46 dosage forms [mean number 3.48, standard deviation (SD) = 1.68; median 3.00, interquartile range (IQR) = 2; range: 2-9]. Nine (30%) antimicrobials (azithromycin, clarithromycin, cefazolin, cefepime, pipemidic acid, ciprofloxacin, levofloxacin, moxifloxacin and gentamicin) had inconsistent information. The inconsistency was related to different classes of interactions, and in some cases it could have clinically important implications (gentamicin, fluoroquinolones). The existence of a larger number of generic products was related to identified differences (p = 0.003). Conclusion. One third of generic antimicrobial products had inconsistent drug-nutrition interaction statements. Given the potential clinical implications, strategies for further harmonization of this information should be considered.
References
Masur H. Foreword. In: Piscitelli SC, Rodvold KA, editors. Drug Interactions in Infectious Diseases. New York: Humana Press Inc; 2005. p. V‒VI.
Invirase®, 500 mg, film tablets [Summary of Products Charac-teristics]. Beograd: Roche DOO, 2017. [cited 2018 Aug 12] Available from: https://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-02378-16-001.pdf).
Schmidt LE, Dalhoff K. Food-Drug Interactions. Drugs 2002; 62(10): 1481‒502.
Djukic LJC, Terzic BM. The availability of reliable information about medicines in Serbia for Health Professionals. Hosp Pharmacol 2015; 2(1): 225‒34.
European Commission. A Guideline on Summary Product Characteristics (SmPC). September 2009. [cited 2018 Aug 10] Available from: https://ec.europa.eu/health/sites/health/ files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf
The European parliament and of the council. DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Communi-ty code relating to medicinal products for human use. [cited 2018 June 21] Available from: https://ec.europa.eu/health/sites/ health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/ dir_2001_83_cons_2012_en.pdf
Theuretzbacher U. Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 2014; 69(7): 1987‒92.
Boyd SA, Charani E, Lyons T, Frost G, Holmes AH. Information provision for antibacterial dosing in the obese patient: a sizea-ble absence? J Antimicrob Chemother 2016; 71(12): 3588‒92.
Sillo HB, Masota NE, Kisoma S, Rago L, Mgoyela V, Kaale EA. Conformity of package inserts information to regulatory re-quirements among selected branded and generic medicinal products circulating on the East African market. PLoS One 2018; 13(5): e0197490.
Karadima V, Kraniotou C, Bellos G, Tsangaris GT. Drug-micronutrient interactions: food for thought and thought for action. EMPA J 2016; 7(1): 10.
Boullata JI, Hudson LM. Drug-nutrient interactions: a broad view with implications for practice. J Acad Nutr Diet 2012; 112(4): 506‒17.
Edwards IR. A New Erice Report Considering the Safety of Medicines in the 21st Century. Drug Saf 2017; 40(10): 845‒9.
Ivanović LJ. Registar lekova 2017. Beograd: BB-Soft; 2017.
Curatolo W, Liu P, Johnson BA, Hausberger A, Quan E, Vendola T, et al. Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC cap-sules. Pharm Res 2011; 28(7): 1531‒9.
Foulds G, Luke DR, Teng R, Willavize SA, Friedman H, Curatolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996; 37 Suppl C: 37‒44.
Péter S, Navis G, de Borst MH, von Schacky C, van Orten-Luiten ACB, Zhernakova A, et al. Public health relevance of drug-nutrition interactions. Eur J Nutr 2017; 56(Suppl 2): 23‒36.
Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005; 85(3): 257‒68.
Landis JR, Koch GG. The measurement of observer agreement for categorial data. Biometrics 1977; 33(1): 159‒74.
San Miguel MT, Martinez JA, Vargas E. Food-drug interactions in the summary of product characteristics of proprietary me-dicinal products. Eur J Clin Pharmacol 2005; 61(2): 77‒83.
Velissaris D, Karamouzos V, Marangos M, Pierrakos C, Karaniko-las M. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature re-view. J Clin Med Res 2014; 6(4): 227‒33.
Kamei C, Sugimoto Y, Muroi N, Tasaka K. Effects of various ce-phem antibiotics on ethanol metabolism and their structure-activity relations. J Pharm Pharmacol 1986; 38(11): 823‒8.
Yanagihara M, Okada K, Nozaki M, Tsurumi K, Fujimura H. Ce-phem antibiotics and alcohol metabolism. Jpn J Antibiot 1985; 38(3): 634‒42.
Rao PS, Goodwani S, Bell RL, Wei Y, Boddu SH, Sari Y. Effects of ampicillin, cefazolin and cefoperazone treatments on GLT-1 expressions in the mesocorticolimbic system and ethanol in-take in alcohol-preferring rats. Neuroscience 2015; 295: 164‒74.
Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 2013; 57(7): 971‒80.
Kabbara WK, Ramadan WH, Rahbany P, Al-Natour S. Evalua-tion of the appropriate use of commonly prescribed fluoro-quinolones and risk of dysglycemia. Ther Clin Risk Manag 2015; 11: 639‒47.
Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hy-poglycemia after antimicrobial drug prescription for older pa-tients using sulfonylureas. JAMA Intern Med 2014; 174(10): 1605‒12.
Eriksson R, Aagaard L, Jensen LJ, Borisova L, Hørlück D, Brunak S, et al. Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulato-ry authorities in Denmark and the USA. Pharmacol Res Per-spect 2014; 2(3): e00038.
Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product information for antidepres-sants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ Open 2016; 6(3): e010599.
Alshammari TM, Devadasu VR, Rathnam RP. Comparison of the safety information on drug labels in three developed coun-tries: the USA, UK and Canada. Saudi Pharm J 2017; 25(8): 1103‒7.
Nanji AA, Denegri JF. Hypomagnesemia associated with gen-tamicin therapy. Drug Intell Clin Pharm 1984; 18(7‒8): 596‒8.
DiNicolantonio JJ, O'Keefe JH, Wilson W. Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. Open Heart 2018; 5(1): e000668.
Duke J, Friedlin J, Li X. Consistency in the safety labeling bio-equivalent medications. Pharmacoepidemiol Drug Saf 2013; 22(3): 294‒301.
Arguello B, Salgado TM, Laekeman G, Fernandez-Llimos F. De-velopment of a tool to assess the completeness of drug infor-mation sources for health care professionals: A Delphi study. Regul Toxicol Pharmacol 2017; 90: 87‒94.
Ni Y, Jensen K, Kouskoumvekaki I, Panagiotou G. NutriChem 2.0: exploring the effect of plant-based foods on human health and drug efficacy. Database (Oxford) 2017; 2017: doi:10.1093/database/bax044.
Hens B, Van Den Abeele J, Rubbens J, Keirsebilck M, Roelens J, Schreurs C, et al. Evaluation of real-life dosing of oral medi-cines with respect to fluid and food intake in a Dutch-speaking population. J Clin Pharm Ther 2017; 42(4): 467‒74.
Pliva, Inc. v. Mensing, 131 S.Ct. 2567 (2011).
Mutual Pharmaceutical Co. v. Bartlett , 133 S.Ct. 2466 (2013).
Rafferty v. Merck & Co., Inc., SJC-12347 (2018).